general transcription factor IIIAGenealiases: AP2 · TFIIIA
Q-omics provides the consensus-scored GTF3A profile across patient tissues and cancer cell-line models. GTF3A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GTF3A is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, GTF3A RNA expression shows 18,567 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KIRC, and THYM as cancer lineages where GTF3A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GTF3A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GTF3A survival associations across molecular data types. GTF3A RNA expression shows survival associations in the most cancer types (25), followed by mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GTF3A RNA expression–survival associations across cancer types. High GTF3A expression shows unfavorable associations in UVM, ACC, KICH, READ, LIHC and ESCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for GTF3A RNA expression.
This table summarizes GTF3A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GTF3A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GTF3A shows higher tumor expression in KIRC, COAD, BLCA, KIRP, READ and LUAD. The KIRC box plot shows higher GTF3A RNA expression in tumor versus normal tissue (log2 FC = +1.240, t-test p < 0.001).
This table shows molecular features associated with GTF3A in patient tissues and cancer cell lines. In patient samples, GTF3A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GTF3A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
